RU2495669C1 - Method of treating degenerative and dystrophic retinal diseases - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to ophthalmology and may be used for treating degenerative and dystrophic retinal diseases. That is ensured by subcutaneous introduction of the preparation Coenzyme compositum 0.5 ml within the mastoid process, the preparation Lymphomyosot - within the temporal fossa, as well as by parabulbar introduction of the preparation Placenta compositum. The course is 10 sessions every second day 1-2 days a year. The introductions are double-sided if the retina in both eyes is involved.

EFFECT: invention provides improving the peripheral circulation in the eyes, increasing visual acuity due to the integrated effect of the drugs administered.

2 cl, 5 ex

Description

The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of degenerative and dystrophic diseases of the retina of various origins.

A significant place in ophthalmology is occupied by age-related macular degeneration and hereditary diseases of the retina, characterized by bilateral lesion and progressive visual damage. These diseases lead to disability of patients of working age, and the development of macular degeneration is one of the main reasons for a significant decrease in vision until blindness occurs in the second half of the patient's life. In recent years, there has been a steady tendency towards an increase in the frequency of dystrophic diseases of the optic nerve and retina, leading to low vision and irreversible blindness in people of different ages. A significant role in the etiopathogenesis of this severe ophthalmopathology is played by general and local vascular disorders that worsen the level of capillary perfusion and trophic processes in the optic-nervous apparatus of the eye (Kiseleva T.N., Polunin G.S., Eliseeva E.G. et al. Modern aspects of pathogenesis and clinic of age-related macular degeneration / Ophthalmology, 2005, Vol. 2, 1, pp. 18-24; Neroev V.V., Malinovskaya T.A., Ivanov A.N. et al. New possibilities in the treatment of involutional central chorioretinal degeneration (CCRD) / Ophthalmology, 2005, T.2, 1, p. 53-56; Klyuev G.O. and SOA t. plazmatsitofereza Effect on rheological properties of the blood and eyes hemodynamics in patients with acute and chronic vascular optikoneyropatiyami / ophthalmia. g-l 2008, 1, s.54-59 et al.).

Improving the functional activity of the retina, retinal electrogenesis and the associated visual functions is undoubtedly the main task of any therapeutic rehabilitation measures for diseases of the retina of various nature (degeneration, dystrophies of various origins, post-traumatic changes, retinal lesions in general diseases).

There are methods of treating degenerative diseases of the retina and optic nerve using numerous pharmacological agents: vasodilator drugs, nootropic drugs, bioregulators, antihypoxants, antioxidants, etc.

Numerous medications, physiotherapeutic methods, laser and surgical interventions are not sufficiently effective (Lysenko BC Development of pathogenetically oriented complex methods of treatment of involutional central chorioretinal dystrophies ". Thesis. Candidate of Medical Sciences. S.5-25). Therefore, clinical improvement is unstable. , the pathological process continues to progress, leading to a significant decrease in vision. Despite the wide selection of commonly used methods of treatment, The development of visual functions remains an urgent problem, hence the need to find new modern ways to improve the functional activity of the retina.

The closest analogue of the proposed method is a method of the same purpose, including conducting a diagnostic autonomic resonance test (ART) with the registration of electrical biopotentials in a reproducible BAT with the simultaneous effect of bipolar pulses on the eye supplied from a magnetic inductor of this apparatus, using frequencies of 7.0; 19.5; 19.75; 50.0; 50.5; 93.5; 65.5; 74.5; 79.5; 93.5; 94.5 Hz, frequencies that do not reach - 80 cu are detected, then the patient’s palms and feet are placed on the plate “hand” and “foot” electrodes for bioresonance therapy - BRT, and the “frontal” electrode for BRT is fixed on an eyeball, on top of the “frontal” electrode there is a magnetic inductor connected to the magnetotherapy socket, then they are exposed to electromagnetic frequencies from 2 or more minutes to obtain electrical indicators in the reproducible BAT that correspond to the norm - 80 cu, a course of 7- 10 daily sessions, immediately after the procedure, they carry out therapy with drugs that enhance the functional activity of nerve fibers RU 2406469, 12/20/2010).

The task of the invention is to develop a new homeopathic method for the treatment of degenerative and dystrophic diseases of the retina of various origins.

The technical result of the proposed method is to improve the functional state of the retina and visual functions.

Technically, the result is achieved due to the effect on the zones of regional blood circulation by injection of the preparations Lymphomyozot, Coenzyme compositum, and Placenta compositum.

As the smallest functional unit of an organism, one should not consider a cell, as Virkhov believed, but a cell with its environment through which it receives food and is freed from metabolic products. The environment surrounding the cell and the surface of the cell must possess such physicochemical properties in order to be able to coordinate its functions. Unfortunately, it is still customary to consider a cell in isolation from its environment, from the extracellular matrix (ECM).

The most important structural components of VKM are proteglycans, glucosaminoglycans (PG, GAG). GHGs are the main component of VKM. They are everywhere in the intercellular spaces. The structure of VKM as a molecular sieve is largely determined by the electronegative molecules of PG and GAG. The most common proteoglycans are chondroitin sulfate (HSPG) and heparan sulfate proteoglycan (SHBG). GHG molecules help to detect a certain topographic ordering in VKM: ChSGH molecules are linked to hyaluronic acid via amino acid residues of their skeleton (H. Heine, Biological Medicine Textbook, Moscow, Arnebia, 2008, pp. 21-24).

According to various authors, between the cytoplasmic membrane of the microvilli of the retinal epithelial cells and the membrane of the photoreceptors, a slit-like space is formed, formed by the interfotoreceptor matrix, which is synthesized by the cells of the pigment epithelium and consists of chondroitin sulfate (60%), sialic (25%) and hyaluronic (15%) Rodriques 1998). The interfotoreceptor matrix is involved in the transfer of retinoid and phagocytosis of the outer segments of the photoreceptors (Geenq-Fu, 2000). Violation of the structural organization of the matrix is the reason for the development of various types of retinal degeneration and retinal detachment (S. Zhukova, A. Schuko, V. Malyshev, Retinal pigment abiotrophy, Moscow, Specialist Library, Ophthalmology, 2010, p. 8).

Unfortunately, since GHGs and GAGs carry electrochemical charges, they also turn out to be structures in which toxins are deposited for a long time. The only way to drain toxins from the matrix is through the lymphatic system. This means that when the matrix is overloaded with toxins, the lymphatic system is also overloaded. In this case, an elementary blockage of the lymph ducts by drained residues of connective tissue is possible. Therefore, stimulation of lymph flow is one of the most important conditions for detoxification of the matrix. (Detoxification and drainage, 2nd Russian edition, 2010, Moscow, Arnebia, pp. 22-24).

The drug Lymphomyozot was developed as a drainage agent, the point of application is the lymphatic system. Studies have shown that in the matrix, this drug activates the end products of glycation (Dietz AR. Adjuvant Homeopatic Treatment of Periferal Diabetic Polyneuropathy, J Biomedical Therapy, 2004, winter 12).

Degeneration of cellular structures is associated with impaired glycolysis and oxidative phosphorylation. In this case, the use of cellular biochemical metabolites responsible for the work of the Krebs cycle is of particular importance. The use of catalysts plays a significant role in the restoration of cellular functions. Coenzyme compositum has a complex composition, contains potentiated vitamins, elements of the Krebs cycle, enzymes, potentiated trace elements. These substances have a stimulating effect, not leading to their deposition, nor to the occurrence of hypersensitivity, nor to addiction (Ivo Bianchi, Geriatrics and Homotoxicology, Arnebia, 2002, Russian edition, pp. 78-86).

The next task in conducting therapy is to improve peripheral blood circulation and microcirculation of the organ of vision. The placenta compositum preparation contains a complex of biogenic polypeptides that have a revitalizing and activating effect on peripheral blood flow, and have a venotonic, vasodilating and antispastic effect. To date, the efficacy of the placenta compositum drug has been proven in the treatment of macular degeneration with intramuscular administration and by electrophoresis (A. Maryanovsky, G. Radysh, Journal of Biological Medicine, 2005, pp. 30-33).

In our proposed method, the drug is administered parabulbarno. Parabulbar administration of a complex antihomotoxic drug does not cause any local or allergic reaction, is well tolerated by patients.

Thus, the use of three drugs - Lymphomyozot, Coenzyme compositum. The placenta of the compositum makes it possible to influence various pathological links that play a crucial role in degenerative and dystrophic diseases of the retina of various origins and simultaneously solve several tasks at once: improving intercellular metabolism through detoxification of ECM, increasing intracellular energy, due to optimization of intracellular respiration, and improving microcirculation of the organ of vision . Thus, a three-step sequential effect is carried out: 1 - detoxification, 2 - increased metabolism, 3 - stimulation of blood flow and exposure to biogenic peptides.

Clinically, this is expressed in increasing visual acuity, expanding visual fields, stabilizing visual functions, subjectively, patients note an increase in visual performance, an improvement in color perception.

The use of this method is indicated for degenerative diseases of the posterior segment of the eyeball: CHRD, PCRD, AMD (dry form), optic atrophy, glaucoma, retinal pigment abiotrophy, diabetic angioretinopathy.

The inclusion in the treatment regimen of exactly the stage of the first stage - detoxification - is the key in this scheme and fundamentally differs from the modern view of the treatment of degenerative eye diseases.

The method is as follows. The skin surface in the area of administration is treated with 70% alcohol. The following zones of regional blood circulation were selected for drug administration: Coenzyme compositum, 0.5 ml, was injected subcutaneously into the mastoid region with an insulin syringe, and Lymphomyozot, 0.5 ml, was injected into the temporal fossa, and the placenta was administered parabulbarly. compositum "in a volume of 0.5 ml. Only 10 sessions every other day 1-2 times a year. All three drugs are administered in one session. If retinal disease occurs in both eyes, the effect is carried out from two sides.

Example 1

Patient B., 74 years old. Registered for glaucoma for 17 years. Notes the lack of objective vision in the left eye over the past year. Located on: Betoptic 1 drop n \ night in both eyes.

Vis OD: 0.5 cyl-2.0 ah 60 = 0.7 IOP = 28 mm according to Maklakov OS: 0 (zero) IOP = 39 mm according to Maklakov

OD: Anterior segment of eye without features. The cornea is transparent, the anterior chamber is of medium depth, the pupil reacts to live light, subcapsular opacities of the lens masses. DZN pale, monotonous, glaucomatous excavation of 0.8, angiosclerosis of vessels, single drusen in the macula.

OS is rejected outwardly by 10 degrees according to Grishberg, calm, at 12 o’clock a flat filter cushion, the cornea is transparent, the anterior chamber is small, the pupil does not react to light, subcapsular opacities of the lens masses. DZN pale monotonous, complete glaucomatous excavation, angiosclerosis of blood vessels.

DS: OD Primary open-angle glaucoma 2 "B". AMD (dry form), OS Glaucoma terminal 4 "C". Retinal angiosclerosis.

The patient was assigned a regimen: Xalatan n / a night in both eyes, Betoptic 2 times a day in both eyes. Conservative treatment was carried out according to the proposed scheme No. 10 3 times a week on Monday, Wednesday and Friday: Sol. Limfomiozoti 0.5 ml to the temporal fossa on both sides, Sol. Coenzimi Compositum 0.5 ml in the area of the mastoid processes, Sol. Placenta Compositum 0.5ml parabulbar from two sides.

At the end of the course at the control examination:

OD 0.5 cyl - 2.0 ax 60 = 1.0 IOP = 22 mm according to Maklakov OS 0 (zero) IOP = 32 according to Maklakov

In dynamics, there was an increase in visual acuity in the right eye, stabilization of IOP, drusen in the fundus became less frequent, smaller.

The patient was recommended to repeat penetrating sinus strabeculectomy on OS, a second course of treatment after 6 months.

Example 2

Patient W., 57 years old. He complained of decreased vision in the right eye over the past 7 years, subjective noted a deterioration in the light and color perception of the right eye.

Objective: OD: 0.1 sph + 0.5 cyl - 0.25 ax 15 = 0.6 13 mm PTH OS: 0.6 sph + 0.5-1.0 12 mm PTH

Anterior segment of the eye: without features. Transparent optical media, phacosclerosis phenomena. DZN is pale pink, the contours are clear. On the right in the macula there are different-caliber drusen, prone to fusion, on the left are para-veolar single small-caliber drusen. Arteries are moderately narrowed, veins are dilated, full-blooded.

DS: OU Mild hypermetropia. AMD (dry form). Phacosclerosis Presbyopia. Retinal angiopathy.

Conservative treatment was carried out according to the proposed scheme No. 10 3 times a week on Monday, Wednesday and Friday: Sol. Limfomiozoti 0.5 ml in the temporal fossa, Sol. Coenzimi Compositum 0.5 ml to the mastoid region, Sol. Placenta Compositum 0.5 ml parabulbarno.

At the end of the course at the control examination:

OD 1,0 OS 1,0

An objective examination showed a decrease in the size of drusen in the right eye and resorption in the left. Subjectively, the patient noted an improvement in distance vision, relief when working at close range, and better light and color perception.

Example 3

Patient C., 70 years old, complained of decreased vision in the distance and near both eyes, noted a sharp deterioration in vision in the right eye over the past year.

VIS OD: 0.03 n / a IOP 14 mm RTN OS: 0.1 sph + 4.0 cyl-1.5 ax 90 = 0.5 IOP 13 mm RTN

The anterior segment of the eye without features, arcus sinilis, cortical opacities of the lens masses, mixed destruction of the vitreous body, preretinal fibrosis on the right. DZN is pale pink, the contours are clear. On the right, there is no macular reflex, the retina in the optical zone is swollen, different-sized drusen, a rough proliferative cord through the entire macula. On the left, the macular reflex is preserved, in the macula there are single drusen. The retinal vessels are corkscrew convoluted, narrow arteries, veins dilated plethora, uneven caliber.

DS: OU Mixed astigmatism. Initial cataract. Hypertensive retinal angiopathy. OD AMD is an edematous form. OS AMD is a dry form.

Conservative treatment was carried out according to the proposed scheme No. 10 3 times a week on Monday, Wednesday and Friday: Sol. Limfomiozoti 0.5 ml in the temporal fossa, Sol. Coenzimi Compositum 0.5 ml to the mastoid region, Sol. Placenta Compositum 0.5 ml parabulbar on both sides.

At the end of the course:

OD: 0.05 n / c

OS: 0.2 sph + 4.0 cyl - 1.5 ax 90 = 0.7

An objective examination showed an improvement in the distance, the macular edema on the right was preserved, on the left the drusen became smaller, partially resolved. Subjectively, the patient noted an improvement in distance vision, relief when working at close range, lack of sensation of eye fatigue, heaviness in the eyelids.

Example 4

Patient B, 76 years old. She complained of decreased vision in both eyes over the past 4 years, notes a sharp deterioration in vision in the right eye over the past year. Twice she underwent courses of conservative therapy in the ophthalmic department regarding AMD, the effect of the treatment was not observed.

Objectively: OD 0.25 sph + 1.0 cyl - 1.5 ax 90 = 0.25

OS 0.3 sph + 2.0 cyl - 3.0 ax 85 = 0.4

OUs are calm, the conjunctiva is subatrophic, arcus sinilis, the anterior chamber is of medium depth, the moisture is transparent, the iris of subatrophin, the pupils react to the light lively, on the right there is an IOL in the posterior chamber, on the left is clouding of the crystalline masses, floating opacities in the vitreous. The fundus: optic nerve discs are pale pink, the contours are clear, the vessels of the retina are convoluted, the arteries are sharply narrowed, the veins are dilated full-blooded, in the macular region there are multiple drainage druses, foci of degeneration with deposition of pigment, the changes are more pronounced on the right.

DS: OU AMD (dry form, dystrophic stage). Retinal angiopathy. OD Artifakia. OS Immature cataract.

Conservative treatment was carried out according to the proposed scheme No. 10 3 times a week on Monday, Wednesday and Friday: Sol. Limfomiozoti 0.5 ml in the temporal lobe, Sol. Coenzimi Compositum 0.5 ml to the mastoid region, Sol. Placenta Compositum 0.5 ml parabulbarno.

At the end of the course at the control examination:

OD 0.4 sph + 1.0 cyl - 1.5 ax 90 = 0.55

OS 0.3 sph + 2.0 cyl - 2.5 ax 85 = 0.5

In dynamics, an increase in visual acuity was noted in both eyes, on the fundus without objective changes. Within 6 months, stabilization of visual functions was noted.

Example 5

Patient A., 26 years old. He complained of low vision in both eyes since childhood.

Objectively: OD 0.4 cyl - 2.0 ax 15 = 0.5

OS 0.4 cyl - 2.0 ax 170 = 0.5

OD is deflected outwardly by 60 degrees according to Hirschberg, the primary angle is equal to the secondary, in the extreme horizontal leads fine-spreading nystagmus, convergence is significantly weakened. OU calm, optical media are transparent, the pupils' reaction to light is lively. The fundus: optic nerve discs are pale pink, the contours are clear, the vessels of the retina are moderately narrowed, on the middle and extreme periphery of the deposition of pigment in the form of "bone cells", the macular reflex is reduced.

DS: OU Retinal pigment abiotrophy. Myopic simple direct astigmatism. Medium refractive amblyopia. Divergent squint. Horizontal nystagmus.

Conservative treatment was carried out according to the proposed scheme No. 10 3 times a week on Monday, Wednesday and Friday: Sol. Limfomiozoti 0.5 ml in the temporal lobe, Sol. Coenzimi Compositum 0.5 ml to the mastoid region, Sol. Placenta Compositum 0.5 ml parabulbarno.

At the end of the course at the control examination:

OD 0.6 cyl - 2.0 ax 15 = 0.7

OS 0.5 cyl - 2.0 ax 170 = 0.7

In dynamics, an increase in visual acuity was noted in both eyes, on the fundus without objective changes. Within 6 months, stabilization of visual functions was noted.

Thus, the proposed method demonstrates an increase in visual functions in patients with degenerative and degenerative diseases of the retina.

Claims (2)

1. A method of treating degenerative and dystrophic diseases of the retina, characterized in that the preparation “Coenzyme compositum” is administered subcutaneously in a volume of 0.5 ml into the region of the mastoid process, the drug “Lymphomyozot” is introduced into the temporal fossa, and the placenta compositum is parabulbar. , a course of 10 sessions every other day 1-2 times a year. 2. The method according to claim 1, characterized in that in case of a disease of the retina of both eyes, administration is carried out from two sides.